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Abstract
Background: Concerns have been raised that extensive use of personal care products that contain endocrine
disrupting compounds increase the risk of hormone sensitive cancers.
Objective: To assess the effect of skincare product use on the risk of pre- and postmenopausal breast cancer,
estrogen receptor positive (ER+) and negative (ER-) breast cancer and cancer of the endometrium.
Methods: We used data from 106,978 participants in the population-based Norwegian Women and Cancer cohort.
Participants were categorized into non-, light, moderate, frequent and heavy users of skincare products based on
self-reported use of hand and facial cream and body lotion. Cancer incidence information from the Cancer Registry
of Norway was linked to individual data through the unique identity number of Norwegian citizens. Multivariable
Cox proportional hazard regression was used to assess the effect of skincare product use on the risk of cancer of
the breast and endometrium. We used multiple imputation by chained equations to evaluate the effect of missing
data on observed associations.
Results: We found no associations between use of skincare products and incidence of premenopausal breast
cancer (frequent/heavy versus non−/light use: hazard ratio [HR] =1.10, 95% confidence interval [CI]: 0.92–1.32),
postmenopausal breast cancer (heavy versus light use: HR = 0.87, 95% CI: 0.65–1.18, frequent versus light use: HR =
0.97, 95% CI: 0.88, 1.07) or endometrial cancer (frequent/heavy versus non−/light use: HR = 0.97, 95% CI: 0.79–1.20).
Use of skincare products did not increase the risk of ER+ or ER- breast cancer and there was no difference in effect
across ER status (0.58 ≤ pheterogeneity ≤ 0.99). The magnitude and direction of the effect estimates based on
complete case analyses and multiple imputation were similar.
Conclusion: Heavy use of skincare products, i.e. creaming the body up to two times per day during mid-life, did
not increase the risk of cancer of the breast or endometrium.
Keywords: Skin care, Body lotion, Hand cream, Facial cream, Personal care products, Cancer, Breast, Endometrial,
Cohort, Carcinoma
Background
Use of skincare products such as body lotion, facial
cream and hand cream is common among Norwegian
women [1]. Several components of these personal care
products (PCPs) are classified as known or suspected
endocrine disruptors (EDs), i.e., compounds that are able
to interfere with the endocrine function in humans and
wildlife [2]. EDs are easily absorbed by the skin into the
central blood circulation after dermal application, and
have been detected in various concentrations in human
blood, urine and breastmilk [3]. Concerns have therefore
been raised whether extensive use of cosmetics and skin-
care products could increase the risk of hormone related
cancer, for instance breast cancer [4].
Among frequently used EDs in PCPs are phthalates,
ultraviolet (UV) filters, triclosan and parabens [5]. Phtha-
lates are also commonly used as softeners in consumer
products such as food packaging material, children’s toys
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and building material [6] and have been suggested to
interfere with the testosterone production or action [2].
Recently, phthalates have shown anti-estrogenic effect in
breast cancer cell lines [7] and induced cell proliferation
in normal breast cells [8]. However, recent epidemio-
logical studies reported no significant association between
phthalate exposure and breast cancer [9, 10].
UV-filters are a large group of compounds used as
constituents in sunscreen as they are able to absorb UV-
radiation. They are also included in other PCPs to in-
crease shelf-life [2], and have been detected in human
urine [11, 12], breastmilk [13] and breast tissue [14].
Many UV-filters exert estrogenic activity in in vivo/
in vitro experiments [15], however epidemiological stud-
ies of endocrine disrupting effects of UV-filters are rare.
Triclosan is primarily used as an antimicrobial agent in
soap, toothpaste, cosmetics and pharmaceuticals and has
shown endocrine disrupting properties in experimental
settings [2]. Prenatal triclosan concentrations was re-
cently reported associated with earlier menarche in
American girls, whereas there was no effect of prenatal
or peripubertal concentrations of the UV filter
Benzophenone-3 [16].
Parabens are alkyl esters of p-hydroxybenzoic acid
which is naturally occurring in several plants and berries,
such as blueberries, strawberries, red and white currants
[17, 18]. For decades, methyl-, ethyl, propyl- and butyl-
paraben were the most frequently used preservatives in
skincare products due to their antimicrobial properties,
low toxicity, cost and weak sensitizing properties. From
the beginning of this century, restrictions on the use of
parabens in consumer products have been implemented
within the European Union as a result of scientific
reporting of weak estrogenic activity of parabens. Several
in vitro studies have shown that parabens are able to
bind to the estrogen receptor and stimulate proliferation
within human breast cancer cell lines [19, 20], also in
concentrations similar to what have been detected in hu-
man breast cancer cells [21] and in human breast tissue
[22]. Subcutaneous exposure to butyl and isobutyl-
paraben has also been linked to uterus enlargement in
rodents as a result of estrogenic activity [23] and peripu-
bertal concentrations of methyl- and propoyl-paraben
have been associated with measures of pubertal timing
in girls [16]. In our previous study, we showed that
women who cream their body once daily or more had el-
evated plasma concentrations of methyl-, ethyl- and pro-
pyl- parabens [24]. Other studies have found similar
results [25], and there are reason to believe that women
who use skincare products frequently experience higher
body burdens of other EDs as well, for instance phtha-
lates, UV filters and triclosan [12, 26].
Epidemiological evidence of the effects of cosmetics,
skincare products or constituents of PCPs on hormone
sensitive cancers, such as cancer of the breast and endo-
metrium, is sparse. A recent cohort study reported 13%
increased risk of breast cancer by frequent use of skin-
care products and 15% increased risk by frequent use of
beauty products [27]. Parada et al. found positive associ-
ations between paraben concentrations in urine (methyl-
propyl and ∑parabens) and prevalent breast cancer, and
negative, non-significant associations with breast cancer
mortality [28]. Out of four case-control studies of anti-
perspirant use and breast cancer risk, two reported no
effect [29, 30] and one found an increased risk of breast
cancer by use of underarm cosmetics [31]. The forth
study reported an association between earlier age at
breast cancer diagnosis and longer duration of deodor-
ant use and underarm shaving [32]. Use of skin light-
eners has recently been reported not being associated
with breast cancer [33]. Thus, given the widespread use
of skincare products and the potential estrogenic effects
of product constituents, there is a clear lack of epi-
demiological studies addressing the effect of skincare
product use on hormone sensitive cancers. In this
population-based study, we aimed to investigate the ef-
fect of skincare product use on the risk of pre- and post-
menopausal breast cancer, estrogen receptor positive
(ER+) and negative (ER-) breast cancer and cancer of
the endometrium.
Methods
Study design, participants and sub-samples
The Norwegian Women and Cancer study (NOWAC) is
a national representative cohort study initiated in 1991
with the aim of exploring associations between lifestyle
and cancer among Norwegian women [34]. Women
aged 30–70 years were randomly selected from the Na-
tional Registry and invited to participate in the study
through a mailed invitation letter to their home address
that also included a detailed questionnaire. Women that
agreed to participate have been followed-up regularly
with consecutive questionnaires. Since the initiation of
the study, the cohort has been expanded several times
and includes today about 172,000 women. All partici-
pants have answered between one and four question-
naires regarding their current health status and lifestyle
factors. The questionnaires have been distributed in
waves and the level of details has varied between the
questionnaires. The external validity of NOWAC has
been studied extensively and been found satisfactory and
without selection bias [35].
Questionnaires that included questions about usage
frequencies of hand cream, facial cream and body lotion
were mailed to 192,648 women, of which 114,794
responded. The questions regarding usage of skincare
products were the same in all questionnaires. We ex-
cluded 1431 women that belonged to a certain wave of
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recruitment that was not randomly sampled and 5
women that died or emigrated before their baseline
questionnaire were registered. Additionally 6286 women
were excluded as they were diagnosed with cancer (ex-
cept non-melanoma skin cancer, International Statistical
Classification of Diseases, Injuries and Causes of Death
Revision 10 code [ICD-10]: C44) prior to answering the
questionnaire. Women reporting implausible values on
height, weight, age at menarche, age at first full term
pregnancy and age at menopause were also excluded
from the study (n = 94). Thus, the final study sample
used for studying the associations between skincare
product use and breast cancer subtypes included 106,
978 women (Fig. 1).
After excluding 85,721 women that were either post-
menopausal (n = 80,245), used menopausal hormone
therapy (MHT, n = 3543) or were ≥ 53 years at baseline
(n = 1933), the study sample for premenopausal breast
cancer included 21,257 women (Fig. 1). Women were
considered postmenopausal if they stated that their men-
strual bleeding had stopped or reported use of MHT if
they were ≥ 53 years. This cut-off is based on the defin-
ition used in the Million Women Study [36] and has
been validated against plasma concentrations of sex hor-
mones in NOWAC [37].
The study sample for postmenopausal breast cancer
included 106,328 women (Fig. 1). Women that were not
categorized as postmenopausal at baseline were included
in the study from the age of 53 years or the age of
reported menopause. Due to this left truncation, we ex-
cluded 567 women that were diagnosed with cancer and
83 that died or emigrated before the start of follow-up.
The study sample for endometrial cancer included 95,
577 women. Here, we excluded women that reported
hysterectomy (n = 11,401).
Measures of skincare products use and included
covariates
In the NOWAC questionnaires, women were asked to
record how often they used skincare products such as
body lotion, hand cream and facial cream (never/seldom,
1–3 times/month, 1 time/week, 2–4 times/week, 5–6
times/week, 1 time/day and ≥ 2 times/day). The recorded
frequencies were converted to percentage body surface
covered with cream per day. Use of hand cream, facial
cream and body lotion once per day corresponded to
100% of body surface covered in cream per day. Calcu-
lated percentages were later categorized into five groups;
non-users (0–0.001%), light users (0.002- < 35.0%), mod-
erate users (35.0- < 65.0%), frequent users (65.0- <
115.0%) and heavy users (115.0–200%), where 200% cor-
responded to using hand cream, facial cream and body
lotion twice per day. The conversion is described in de-
tail in Aniansson et al. [1] and has also been used previ-
ously to assess the correlation between skincare product
use and plasma concentrations of parabens [24].
Information on the women’s age was extracted from
the National Registry and the other covariates from the
Fig. 1 Flow chart of inclusion and exclusion criteria. The Norwegian Women and Cancer cohort 2003–2011
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baseline NOWAC questionnaire. Education was catego-
rized based on years of completed schooling correspond-
ing to secondary school (< 10 years), high school (10–12
years) and higher education (> 12 years). Body mass
index (BMI) was calculated from self-reported body
weight (kg) and height (m), and categorized as under
−/normal weight (< 25.0 kg/m2), overweight (25.0–29.9
kg/m2) or obese (≥30 kg/m2). The women’s menopausal
status (premenopausal, perimenopausal, postmeno-
pausal, unknown) was determined by reported regular
menstrual bleeding or not, use of MHT and the women’s
age [36]. Age at menarche was categorized into three
groups (≤12 years, 13–14 years, ≥15 years) and age at
first full term pregnancy and parity were combined into
one variable (nullipara, < 30 years at first full term preg-
nancy and unipara, ≥30 years and unipara, < 30 years and
multipara, ≥30 years and multipara) in the statistical ana-
lysis. Use of oral contraceptives (OCs) and MHT were
categorized in two ways; never/former/current was used
for the breast cancer analysis, and the never/ever
categorization for endometrial cancer. Use of intrauter-
ine device (IUD) was also assessed as never/ever use.
Smoking status was categorized as never, former and
current smoker. Physical activity was recorded on an or-
dinal 10-point scale and categorized as low (1–4), mod-
erate (5–6) and high (≥7). Alcohol consumption was
recorded by a food frequency questionnaire and used in
continuous scale.
Cancer incidence, tumor receptor status, death and
emigration
The NOWAC study receives annual updates from the
Cancer Registry of Norway in order to identify study par-
ticipants diagnosed with cancer during the preceding year.
Information on date of diagnosis and hormone receptor
status for the breast cancer cases are also included. In the
present study, women diagnosed with a first primary inva-
sive malignant neoplasm of the breast (ICD-10: C50) and
uterus (ICD-10: C54) were identified. Endometrial cancer
cases were identified from morphological codes 8380,
8382, 8480, 8481, 8560, 8570, 8020, 8041, 8045, 8255,
8310, 8441, 8460 or 8323 from the International Classifi-
cation of Disease for Oncology ICD-O-3. Information
about deaths and emigration was extracted from the
Causes of Death Registry and the National Registry. End
of follow-up was December 31, 2016.
We followed the official Norwegian thresholds for clas-
sification of hormone receptor status [38]. From February
2012 and onwards, a tumor was classified as ER- if it dis-
played < 1% reactivity, whereas prior to February 2012, the
threshold for ER- was < 10%. Accordingly, tumors classi-
fied as ER+ displayed ≥10% reactivity prior to February
2012 and ≥ 1% after. The change in threshold was due to
changes in clinical practice at Norwegian hospitals.
Statistical analysis
We investigated the associations between skincare prod-
uct use and the risk of breast and endometrial cancer
using Cox proportional hazard regression with age as
the time scale. Entry time was age at answering the
questions on skincare products, and exit time was age at
cancer diagnosis, death, emigration or end of follow-up,
whichever occurred first. In the analysis of premeno-
pausal breast cancer, women were censored at the age of
53 or age at reported menopause if that occurred prior
to cancer diagnosis, death, emigration or end of follow-
up. Due to few cancer cases among the non- and heavy
users of skincare products, we used three exposure
groups (non−/light, moderate, frequent/heavy) in the
analysis of premenopausal breast cancer, endometrial
cancer and the subtype-specific analysis of breast cancer.
Light users (or non−light users) were used as the refer-
ence group in all analysis. We used the “purposeful se-
lection method” described by Hosmer and Lemeshow
[40] to evaluate which covariates to include in the final
multivariable models. Covariates included in each re-
gression model are listed in the table footnotes. To test
for linear trend, we replaced the group identifier with
the median use of % skin covered in cream per day per
group, and included that variable in the multivariable
models. Additionally, to model the relationship between
cancer risk and use of skincare products in continuous
scale and to allow for non-linear effects, we fitted regres-
sion models with natural cubic spline transformations (4
knots) of the exposure variable (% skin creamed per
day). The knots were placed at equally spaced percen-
tiles. We evaluated non-linearity by testing the null hy-
pothesis of the second and third spline coefficients
jointly equalled zero. We assessed effect modification by
MHT use for postmenopausal breast cancer, but did not
evaluate any other interactions, due lack of statistical
power. Departures from the proportional hazard as-
sumption were assessed by inspection of the Schoen-
feldts residuals. Participants with missing values of
included covariates were excluded from the complete
case analysis.
To assess differences in sub-type specific breast cancer
risk, we used Cox proportional hazard regression for
ER+ and ER- separately, where women who were diag-
nosed with another breast cancer subtype, were censored
at the time of diagnosis [41]. We tested for heterogeneity
in associations between subtypes by a chi-squared (con-
trast) test [42].
In the complete case analysis of premenopausal breast
cancer, 92% of the observations were included. Corre-
sponding proportions for postmenopausal breast cancer,
ER+, ER- breast cancer and endometrial cancer were 83,
84, 90 and 69%, respectively. To evaluate the effect of
missing information on the observed results, we used
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multiple imputation by chained equations to obtain 20
imputed datasets with complete observations for each
outcome. The hazard ratios (HRs) estimated on the im-
puted data sets were pooled together using Rubin’s rule
to obtain valid statistical inferences [43].
Several additional analyses were performed. We
assessed the associations between recorded usage fre-
quencies of body lotion (categorized as never/seldom, 1–
4 times/month, 2–6 times/week and 1- ≥ 2 times/day)
and breast and endometrial cancer incidence. Further-
more, we summarized the usage frequencies of skincare
products (scores from 0 [no use of any of skincare prod-
ucts] to 18 [use of hand cream, facial cream and body lo-
tion ≥2 times/day]; categorized as low [0–5], moderate
low [6–10], moderate high [11–14] and high [15–18])
and studied the associations with risk of breast and
endometrial cancer.
All P-values were two-sided and a 5% level of signifi-
cance was used. The statistical analysis was conducted
using Stata, version 15.1 (StataCorp, College Station,
TX, USA).
Results
In the total study sample of 106,978 women, mean
(standard deviation [SD]) age at enrollment was 54.7
(4.8) years. During the mean follow-up time of 10.7 (2.6)
years, 3408 women were diagnosed with breast cancer
and 681 with endometrial cancer. Mean age at breast
and endometrial cancer diagnosis were 60.1 (5.5) and
61.0 (5.2) years, respectively.
Age at enrollment was similar in all categories of skin-
care product use. Compared to light users, a larger pro-
portion of women with under−/normal weight and
postmenopausal status were found among the heavy
users. Further, heavy users were slightly younger when
they had their first child and a larger proportions had <
3 children compared to the light users. Heavy users were
also more frequent current and former users of OC,
MHT and cigarettes, more physically active and reported
higher intake of alcohol than the light users (Table 1).
Frequent/heavy users of skincare products did not ex-
perience increased risk of premenopausal breast cancer
(HR = 1.10, 95% confidence interval [CI]: 0.92–1.32),
postmenopausal breast cancer (heavy versus light use:
HR = 0.87, 95% CI: 0.65–1.18, frequent versus light use:
HR = 0.97, 95% CI: 0.88, 1.07) or endometrial cancer
(HR = 0.97, 95% CI: 0.79–1.20) compared to the non
−/light users. Nor did the moderate users, and there was
no linear trend across effect estimates (0.27 ≤ ptrend ≤
0.63) In fact, moderate use of skincare products was as-
sociated with 23% decreased risk of endometrial cancer
(HR = 0.77, 95% CI: 0.61, 0.98) (Table 2). The regression
models with natural cubic spline transformations of
%skin covered in cream per day, displayed no increased
risk of pre- or postmenopausal breast cancer or endo-
metrial cancer by increasing use of skincare products.
However, an inverse association between skincare prod-
uct use and postmenopausal breast cancer risk was sug-
gested (Fig. 2 and Additional file 1). Further, there was
no evidence of an interaction between skincare product
use and MHT use in relation to postmenopausal breast
cancer risk (p interaction(Wald test) = 0.44).
The subtype-specific breast cancer analyses suggested
no increased risk of ER+ or ER- breast cancer by moder-
ate or frequent/heavy use of skincare products and no
difference in effect by estrogen receptor status (0.58 ≤
pheterogeneity ≤ 0.99, Table 3).
The magnitude and direction of the effect estimates
based on complete case analyses and multiple imput-
ation were similar, except for the lack of inverse associ-
ation between moderate skincare product use and risk of
endometrial cancer (Additional files 2 and 3). Thus,
missing values did not bias the observed associations in
the complete case analyses.
In the additional analyses, we found no significant as-
sociations between usage frequencies of body lotion and
the risk of pre- or postmenopausal breast cancer, endo-
metrial cancer, ER+ or ER- breast cancer (body lotion:
0.30 ≤ ptrend ≤ 0.55) (Additional file 4). However, there
was a significant inverse trend for usage frequencies of
skincare products combined and postmenopausal breast
cancer and ER+ breast cancer (0.02 ≤ ptrend ≤ 0.046), al-
though we did not find significantly reduced HRs for
any of the categories (postmenopausal breast cancer:
moderate low versus low use: HR = 1.01, 95% CI: 0.88,
1.17; moderate high versus low use: HR = 0.94, 95% CI:
0.81,1.08; high versus low use: HR = 0.89, 95% CI: 0.77,
1.03; ER+ breast cancer: moderate low versus low use:
HR = 1.07, 95% CI: 0.91,1.24; moderate high versus low
use: HR = 0.95, 95% CI: 0.82,1.11; high versus low use:
HR = 0.93, 95% CI: 0.80,1.09) (Additional file 5). Endo-
metrial cancer and ER- breast cancer were not associ-
ated with usage frequencies of skincare products
combined (0.20 ≤ ptrend ≤ 0.45) (Additional file 5).
Discussion
In this large and national representative cohort of
women in Norway, we found no evidence of increased
risk of pre- or postmenopausal breast cancer by use of
skincare products. Nor did we observe evidence of in-
creased risk of ER+ or ER- breast cancer or endometrial
cancer. We have previously reported that frequent and
heavy users of skincare products in the NOWAC study
experience elevated plasma concentrations of methyl-,
ethyl and propyl-parabens, compounds that exert endo-
crine disrupting properties and have been linked to
breast cancer in in vivo and in vitro studies, as well in a
recent case control study [28, 44, 45]. We can now
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Table 1 Characteristics of study participants (n = 100,436) a by categories of skincare product use
Characteristics Non-users Light users Moderate users Frequent users Heavy users
n 1840 36,598 25,718 34,203 2077
% skin creamed per day 0–0.001 0.002- < 35.0 35.0- < 65.0 65.0- < 115.0 115.0–200
Incident cases of breast cancer (n) 65 1176 801 1088 58
Breast cancer subtype, % b
ER+ 83.1 83.8 85.3 84.1 84.5
ER- 15.4 13.9 12.1 12.9 15.5
Incident cases of endometrial cancer (n) 15 261 141 216 9
Age at enrollment (years), mean ± SD 54.8 ± 5.0 54.3 ± 4.8 54.9 ± 4.8 54.8 ± 4.8 54.8 ± 4.8
Education (years), %
< 10 27.2 15.9 17.0 15.4 15.1
10–12 30.4 32.1 36.4 36.1 34.8
> 12 42.4 51.9 46.5 48.5 50.1
BMI, %
Under−/Normal weight 36.6 50.7 56.7 60.5 66.4
Overweight 33.4 34.8 32.7 30.7 25.7
Obese 30.0 14.5 10.6 8.8 7.9
Menopausal status at enrollment, %
Pre 14.2 15.7 13.0 13.4 13.4
Peri 9.2 10.3 9.5 9.4 8.9
Post 72.4 68.6 72.2 71.5 72.1
Unknown 4.2 5.4 5.2 5.7 5.6
Age at menarche, mean ± SD 13.2 ± 1.5 13.3 ± 1.4 13.3 ± 1.4 13.2 ± 1.4 13.2 ± 1.5
Age at first full term pregnancy, mean ± SD 23.9 ± 4.6 24.4 ± 4.7 24.0 ± 4.4 24.0 ± 4.4 23.9 ± 4.4
Parity, %
0 10.3 10.2 9.3 9.2 10.4
1–2 47.3 53.3 56.7 59.4 58.3
≥3 42.4 36.6 33.9 31.4 31.3
OC use, %
Never 48.2 40.3 38.1 36.0 36.4
Former 51.3 59.2 61.4 63.4 62.8
Current 0.5 0.5 0.5 0.6 0.8
MHT use, %
Never 69.7 63.7 56.7 53.7 50.8
Former 21.4 23.5 27.4 27.2 27.3
Current 8.9 12.8 16.0 19.0 21.8
IUD use, %
Ever 7.7 11.6 11.9 12.2 12.7
Smoking, %
Never 37.4 36.0 32.4 31.0 31.6
Former 30.9 40.8 43.9 45.4 43.6
Current 31.7 23.2 23.7 23.6 24.8
Physical activity, %
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conclude that these women did not experience increased
risk of hormone sensitive cancers. In fact, an inverse re-
lationship between skincare product use modelled in
continuous scale with restricted cubic splines and post-
menopausal breast cancer risk was observed, which
could be a chance finding or a result of residual
confounding.
To this date, our study is the largest prospective co-
hort study assessing the effect of skincare product use
on cancer risk. Our results may seem to contrast Taylor
et al. who recently reported increased risk of breast can-
cer by frequent use of skincare products among non-
Hispanic white women from the United States [27].
However, that study included both in situ and invasive
breast cancer and stratified analyses displayed no signifi-
cant association between frequent use of skincare prod-
ucts and invasive breast cancer, which is in
correspondence with our results. Further, the authors
found no significant associations between skincare prod-
uct use and ER+ or ER- breast cancer which is in line
with our findings. Notably, Taylor and colleagues
included nine different skincare products (face cream,
cleansing cream, anti-aging cream, foot cream, body lo-
tion, hand lotion, petroleum jelly, and two different tal-
cum powders) in comparison to three in the present
study, which could explain differences in results. In the
analyses stratified by breast cancer type, Taylor et al. ob-
served a borderline significant increased risk of in situ
breast cancer among frequent users of skincare products
compared to infrequent users, which may suggest that
the association with skincare product use may be differ-
ent in in situ and invasive breast cancer. Additionally,
skincare product constituents in the United States and
in Europe may vary due to differences in regulations,
which could also affect the results.
Recently, Parada et al. reported positive associations
between urinary concentrations of parabens and breast
cancer status that may seem to contrast our results [28].
It is, however, challenging to compare two such different
studies of which one rely on self-reported skincare prod-
uct use collected years prior to breast cancer diagnosis
and the other on paraben measurements in urine
Table 1 Characteristics of study participants (n = 100,436) a by categories of skincare product use (Continued)
Characteristics Non-users Light users Moderate users Frequent users Heavy users
Low 37.6 24.8 19.8 16.5 14.6
Moderate 34.8 41.8 42.4 38.9 32.6
High 27.6 33.4 37.8 44.6 52.8
Alcohol intake (g/day), mean ± SD 2.7 ± 4.2 3.7 ± 4.3) 4.1 ± 4.2 4.4 ± 4.3 4.2 ± 4.4
SD standard deviation, ER estrogen receptor, BMI body mass index, OC oral contraceptive, MHT menopausal hormone therapy, IUD intrauterine device
a6542 participants had missing values on skincare product use
bPercentage of ER+/ER- subtypes does not add up to 100 due to missing values on hormone receptor status
Table 2 Associations between skincare product use and incidence of pre−/postmenopausal breast and endometrial cancer
User groups of skincare products per cancer type n Cancer cases Age-adjusted HR (95% CI) Multivariable HR (95% CI) ptrend
Premenopausal breast cancera
Non−/Light users 7988 238 1.00 1.00 0.56
Moderate users 4642 146 1.05 (0.86,1.30) 1.05 (0.85,1.29)
Frequent/heavy users 7215 237 1.11 (0.93,1.33) 1.10 (0.92,1.32)
Postmenopausal breast cancerb
Non-users 1549 49 1.12 (0.84,1.49) 1.14 (0.85,1.52) 0.27
Light users 32,379 922 1.00 1.00
Moderate users 22,762 656 1.00 (0.90, 1.10) 0.99 (0.89,1.09)
Frequent users 29,874 854 0.99 (0.90, 1.09) 0.97 (0.88,1.07)
Heavy users 1752 45 0.89 (0.66, 1.20) 0.87 (0.65,1.18)
Endometrial cancerc
Non−/Light users 25,774 213 1.00 1.00 0.63
Moderate users 16,556 98 0.70 (0.55,0.88) 0.77 (0.61,0.98)
Frequent/heavy users 23,156 163 0.83 (0.68,1.02) 0.97 (0.79,1.20)
HR hazard ratio, CI confidence interval
aMultivariable adjusted for maternal breast cancer history and alcohol intake
bMultivariable adjusted for body mass index, use of menopause hormone therapy, age at first birth and parity combined, maternal breast cancer history, physical
activity and alcohol intake
cMultivariable adjusted for body mass index, use of oral contraceptives, use of intrauterine device, smoking and education
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samples collected after breast cancer diagnosis. Clearly,
Parada et al. showed that women with breast cancer ex-
perienced slightly higher concentrations of parabens
compared to healthy controls, however reverse causation
cannot be fully ruled out as the samples were donated
after disease diagnosis.
Our results further suggest that use of skincare prod-
ucts does not increase the risk of endometrial cancer, an
estrogen sensitive cancer type that have increased in in-
cidence over the last 50 years in Norway [46]. In fact,
compared to non−/light users of skincare products,
moderate users experienced 23% decreased risk of endo-
metrial cancer. However, due to the lack of linear trend
across effect estimates and the lack of inverse association
when modelling skincare product use in continuous
scale and after multiple imputation, we consider this a
random finding.
Use of PCPs is considered an important source of
paraben exposure for humans [5, 12]. Several in vivo and
in vitro studies have also demonstrated that parabens
have the ability to interfere with the endocrine system
and may increase the risk of breast cancer through vari-
ous mechanisms [21, 22, 47, 48]. As a consequence, the
use of parabens in consumer products within the
European Union has been restricted and other biocides
such as isothiazolinones have been introduced as re-
placements compounds. Lately, concern have been
raised by dermatologists as these compounds poses
Fig. 2 Associations between skin care product use and pre- and postmenopausal cancer, endometrial cancer and estrogen receptor positive
(ER+) and negative (ER-) breast cancer. Skin care product use is modelled in continuous scale using restricted cubic spline transformations of “%
skin covered in cream per day” with 4 knots. The p-value corresponds to the null hypothesis that the regression coefficient for the second and
third spline transformations equaled zero, i.e., a test of non-linearity




























585 0.98 (0.88,1.08) 0.98 (0.89,1.09) 23,
475
92 0.89 (0.69,1.15) 0.91 (0.7,1.18) 0.58
Frequent/heavy users 35,
784
948 0.99 (0.90,1.09) 0.99 (0.90,1.08) 37,
896
159 0.95 (0.76,1.19) 0.99 (0.79,1.23) 0.99
HR hazard ratio, CI confidence interval; ER: estrogen receptor
aMultivariable adjusted for body mass index, smoking, age at first birth and parity combined, alcohol intake, physical activity, menopausal status, maternal breast
cancer history and use of menopause hormone therapy
bMultivariable adjusted for physical activity and maternal breast cancer history
cTest of difference in effect by breast cancer subtypes
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much stronger sensitizing properties than parabens and
an increasing incidence of allergic contact dermatitis is
therefore expected [49]. As there is a lack of epidemio-
logical evidence of the effects of parabens on human
health, one may question whether replacing parabens
with a more potent sensitizer is wise? There are how-
ever, several possible explanations for the disagreement
between in vivo/in vitro studies and epidemiological
studies that include i) the exposure classification in large
scale epidemiological studies is challenging, as exposure
usually is estimated from questionnaires. This limits the
individual exposure assessment as detailed plasma con-
centration of EDs for each participant is not available.
The questionnaire based approach has however been
used for decades in nutritional epidemiology and if a
proper validation study is performed, as in the our pervi-
ous study [24], the questionnaires will be able to rank in-
dividuals into broader categories based on their
exposure to EDs from PCPs. ii) It is possible that
humans have a different susceptibility to EDs compared
to cell lines and experimental animals and that effects
seen in in vivo and/or in vitro studies are not as pro-
nounced among humans. Animal models will continue
to provide important insight into the human biology,
however there are also important differences between
mice and men that needs to be addressed [50]. iii) The
exposure measure in epidemiological studies may not
necessarily cover exposure during etiological relevant pe-
riods. A large challenge when studying EDs in relations to
hormone sensitive cancers is the limited knowledge about
which period in life humans are most susceptible for ED
exposure in relation to the outcome of interest. Recently,
Harley et al. reported that urinary concentrations of para-
bens at age 9 were associated with earlier breast develop-
ment, menarche and development of pubic hair [16]. They
also found that prenatal triclosan concentrations were asso-
ciated with earlier menarche. Thus, this study suggest that
prenatal and peripubertal exposure to EDs from PCPs may
modify important risk factors for breast and endometrial
cancer, such as age at menarche. Many questionnaire-based
epidemiological studies assess exposure during the previous
year and assume that it reflect past exposure. However, as
lifestyle and consumers products often change from pu-
berty to adulthood, the exposure assessed later in life does
not necessarily reflect exposure during etiologically sensi-
tive time windows. Thus, due to the widespread use of cos-
metics and skincare products among young women today,
the precautionary principle of phasing out potentially
harmful EDs may be favorable even though they may be re-
placed by compounds with stronger sensitizing properties.
However, there is clearly a lack of epidemiological studies
that assess the effect of ED exposure from PCPs during
various life-phases and the subsequent risk of hormone re-
lated cancer.
The strengths of this study includes the large and na-
tional representative sample, the linkage to national regis-
tries that ensures complete information about death,
emigration and cancer diagnosis and the detailed informa-
tion about sociodemographic, reproductive and lifestyle
variables that we included in our analyses. Our previous
study of plasma concentrations of parabens in relation to
reported use of skincare products confirmed that individ-
uals classified as frequent or heavy users of skincare prod-
ucts experience elevated circulatory concentrations of
methyl-, ethyl- and propyl parabens compared to the non-
users [24]. Philippat et al. also confirmed a positive associ-
ation between the number of PCPs used and increasing
urinary paraben concentrations. They further suggested
that questionnaires can be used to measure exposure to
parabens [12]. However, skincare products are not only
sources of parabens; they are sources of other EDs with
different properties and mechanisms of action, individu-
ally and as mixtures. As we have not measured other EDs
than parabens in plasma from skincare products users in
NOWAC, we cannot be certain that those classified as fre-
quent or heavy users also experienced the highest concen-
trations of other EDs such as phthalates, UV filters and
triclosan that individually or combined may exert estro-
genic activity.
We have previously assessed the change in use of skin-
care products over an eight year period. We found mod-
erate agreement (weighted kappa: 0.52) and that almost
92% of women were classified into the same user group
±1 category [1]. Thus, the use of skincare products
among these middle-aged women is a well-established
habit that is relatively stable over time. Nevertheless, we
cannot assume that the reported use of skincare prod-
ucts reflect exposure during childhood/puberty/adoles-
cence. In fact, given the advanced age of the study
participants, it is likely that their use of skincare prod-
ucts during childhood and adolescence were lower than
what is common among children and adolescents today
as the general Norwegian household economy was much
weaker in the 1950’s and 60’s than nowadays and the
availability to skincare products were much more lim-
ited. Caution should therefore be made if generalizing
these results to younger birth cohorts (born 1960 and
onwards).
The NOWAC questionnaires did not include ques-
tions about which part of the body that was covered in
body lotion; therefore we assumed that one application
of body lotion covered nearly the whole body (91%).
This may be seen upon as a limitation as many women
only use body lotion on arms and legs, suggesting that
our measure “% skin covered in cream per day” may
overestimate the exposure. However, we have previously
shown that “% skin covered in cream per day” was
strongly associated with plasma concentrations of
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parabens within the NOWAC cohort [24], and we be-
lieve that this measure better reflect blood concentra-
tions of EDs from skincare product use than the
frequency of use. Nevertheless, we conducted several
additional analyses of reported usage frequencies of skin-
care products (Additional files 4 and 5). These analyses
confirmed our main results, i.e. no increased risk of
breast or endometrial cancer by frequent use of skincare
products. Still, it is possible that some NOWAC partici-
pants over- or under-reported their usage frequencies of
skincare products. As all information was collected be-
fore cancer diagnosis, this measurement error is likely
non-differential. In our age-adjusted models, assuming
non-differential, nonsystematic errors, misclassification
would attenuate the HR of the higher skincare category,
but the test for trend would be valid [51]. As we have
several exposure categories and many confounding vari-
ables included in our multivariable models, non-
differential misclassification can bias the estimates both
towards and away from the null [51].
Our study was also unable to address whether the lo-
cation of body lotion application was associated with
breast or endometrial cancer risk. This may be import-
ant if dermal absorption of EDs on specific areas is more
relevant for breast/endometrial carcinogenesis than con-
tinuously elevated systemic concentrations. Finally, we
did not have information on antiperspirant and cosmetic
use, which could be important sources of paraben expos-
ure. Nevertheless, previous studies have called for epi-
demiological investigations in order to confirm or refute
in vivo/in vitro findings regarding paraben exposure and
the risk of breast cancer. Our finding that use of skin-
care products during mid-life was not associated with
breast and endometrial cancer risk adds important
knowledge to this research field.
Conclusion
Our population-based prospective cohort study provides
evidence that heavy use of skincare products, i.e. creaming
the body up to two time per day during mid-life, does not
increase the risk of pre- or postmenopausal breast cancer,
ER+ or ER- breast cancer or endometrial cancer.
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